AC Immune SA
| NASDAQ: ACIU | Healthcare / Biotechnology / Switzerland |
| 6.67 | +0.0500 | +0.76% | Vol 171.36K | 1Y Perf -6.68% |
| Apr 13th, 2021 16:00 DELAYED |
| BID | 6.61 | ASK | 6.98 | ||
| Open | 6.62 | Previous Close | 6.62 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 15.50 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 132.38 | Finscreener Ranking | ★★★★★ 59.28 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★+ 54.03 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★★ 61.17 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 479.82M | Earnings Rating | Neutral | |
| Price Range Ratio 52W % | 26.22 | Earnings Date | 3rd May 2021 |
Today's Price Range 6.556.82 | 52W Range 4.4213.00 | 5 Year PE Ratio Range -43.9054.70 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -4.85% | ||
| 1 Month | -14.49% | ||
| 3 Months | 8.99% | ||
| 6 Months | 34.48% | ||
| 1 Year | -6.68% | ||
| 3 Years | -25.39% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -11.62 | |||
ROE last 12 Months | -25.49 | |||
ROA (5Y Avg) | -7.23 | |||
ROA last 12 Months | -23.12 | |||
ROC (5Y Avg) | -13.15 | |||
ROC last 12 Months | -23.25 | |||
Return on invested Capital Q | -8.59 | |||
Return on invested Capital Y | -25.07 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 1.70 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -7.20 | ||||
| 2.17 | ||||
| 108.06 | ||||
| 8.90 | ||||
| -8.50 | ||||
| -0.89 | ||||
| 2.06 | ||||
| 3.18 | ||||
| 262.12M | ||||
| Forward PE | -76.33 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 16.30 | ||||
| 16.50 | ||||
| 0.01 | ||||
| 0.01 | ||||
| -335.50 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -386.40 | ||||
| -374.40 | ||||
| -245.90 | ||||
| -51.92 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.57M | ||||
| 0.06 | ||||
| 25.97 | ||||
| -0.91 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.29 | -0.30 | -3.45 |
| Q03 2020 | -0.24 | -0.28 | -16.67 |
| Q02 2020 | -0.28 | -0.23 | 17.86 |
| Q01 2020 | -0.17 | -0.10 | 41.18 |
| Q04 2019 | -0.22 | -0.28 | -27.27 |
| Q03 2019 | -0.06 | 0.25 | 516.67 |
| Q02 2019 | -0.24 | -0.23 | 4.17 |
| Q01 2019 | 1.34 | 0.84 | -37.31 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.21 | 67.69 | Positive |
| 6/2021 QR | -0.21 | 71.62 | Positive |
| 12/2021 FY | -0.46 | - | - |
| 12/2022 FY | -0.09 | - | - |
| Next Report Date | 3rd May 2021 |
| Estimated EPS Next Report | -0.21 |
| Estimates Count | 3 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 171.36K |
| Shares Outstanding | 71.94M |
| Trades Count | 1.06K |
| Dollar Volume | 6.55M |
| Avg. Volume | 901.58K |
| Avg. Weekly Volume | 157.44K |
| Avg. Monthly Volume | 257.41K |
| Avg. Quarterly Volume | 945.41K |
AC Immune SA (NASDAQ: ACIU) stock closed at 6.67 per share at the end of the most recent trading day (a 0.76% change compared to the prior day closing price) with a volume of 171.38K shares and market capitalization of 479.82M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 132 people. AC Immune SA CEO is Andrea Pfeifer.
The one-year performance of AC Immune SA stock is -6.68%, while year-to-date (YTD) performance is 29.01%. ACIU stock has a five-year performance of %. Its 52-week range is between 4.42 and 13, which gives ACIU stock a 52-week price range ratio of 26.22%
AC Immune SA currently has a PE ratio of -7.20, a price-to-book (PB) ratio of 2.17, a price-to-sale (PS) ratio of 108.06, a price to cashflow ratio of 8.90, a PEG ratio of 2.32, a ROA of -23.12%, a ROC of -23.25% and a ROE of -25.49%. The company’s profit margin is -51.92%, its EBITDA margin is -374.40%, and its revenue ttm is $4.57 Million , which makes it $0.06 revenue per share.
Of the last four earnings reports from AC Immune SA, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.21 for the next earnings report. AC Immune SA’s next earnings report date is 03rd May 2021.
The consensus rating of Wall Street analysts for AC Immune SA is Strong Buy (1), with a target price of $15.5, which is +132.38% compared to the current price. The earnings rating for AC Immune SA stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AC Immune SA has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AC Immune SA has a Sell technical analysis rating based on Technical Indicators (ADX : 37.50, ATR14 : 0.68, CCI20 : -155.98, Chaikin Money Flow : -0.17, MACD : 0.03, Money Flow Index : 50.20, ROC : -14.05, RSI : 49.86, STOCH (14,3) : 10.30, STOCH RSI : 0.16, UO : 32.01, Williams %R : -89.70), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AC Immune SA in the last 12-months were:
AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.
CEO: Andrea Pfeifer
Telephone: +41 216939121
Address: EPFL Innovation Park, Lausanne 1015, , CH
Number of employees: 132
